Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial

BACKGROUND: The extent to which response and survival benefits with immunotherapy-based regimens persist informs optimal first-line treatment options. We provide long-term follow-up in patients with advanced renal cell carcinoma (aRCC) receiving first-line nivolumab plus ipilimumab (NIVO+IPI) versus...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Immunother Cancer
Päätekijät: Motzer, Robert J, Escudier, Bernard, McDermott, David F, Arén Frontera, Osvaldo, Melichar, Bohuslav, Powles, Thomas, Donskov, Frede, Plimack, Elizabeth R, Barthélémy, Philippe, Hammers, Hans J, George, Saby, Grünwald, Viktor, Porta, Camillo, Neiman, Victoria, Ravaud, Alain, Choueiri, Toni K, Rini, Brian I, Salman, Pamela, Kollmannsberger, Christian K, Tykodi, Scott S, Grimm, Marc-Oliver, Gurney, Howard, Leibowitz-Amit, Raya, Geertsen, Poul F, Amin, Asim, Tomita, Yoshihiko, McHenry, M Brent, Saggi, Shruti Shally, Tannir, Nizar M
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BMJ Publishing Group 2021
Aiheet:
Clinical/Translational Cancer Immunotherapy
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7359377/
https://ncbi.nlm.nih.gov/pubmed/32661118
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000891
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia